<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Protective effects of bone marrow stromal cells (MSCs) on ischemic brain damage have been highlighted </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the possibility that deletion of AT(2) receptor could attenuate the cerebroprotective effects of MSC using AT(2) receptor-deficient mice (Agtr2 (-)) and the effect of selective AT(1) receptor blocker </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:mp ids='MP_0002169'>Wild-type</z:mp> mice (Agtr2 (+)) were subjected to 3 hours of focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> followed by reperfusion (<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury) </plain></SENT>
<SENT sid="3" pm="."><plain>Simultaneously, Agtr2 (+)-MSC, Agtr2 (-)-MSC, or saline was injected through the tail vein </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Survival rates at 6 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury were as follows: approximately 50% in saline-injected mice, 80% in Agtr2 (+)-MSC-injected mice, and 20% in Agtr2 (-)-MSC-injected mice </plain></SENT>
<SENT sid="5" pm="."><plain>Neurological deficit after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury was improved in Agtr2 (+)-MSC-injected mice, but not in Agtr2 (-)-MSC-injected mice </plain></SENT>
<SENT sid="6" pm="."><plain>After 48 hours of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury, brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size was reduced in Agtr2 (+)-MSC-injected mice, but not in Agtr2 (-)-MSC-injected mice </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, <z:hpo ids='HP_0002181'>brain edema</z:hpo> was significantly ameliorated in Agtr2 (+)-MSC-treated mice but not in Agtr2 (-)-MSC-treated mice </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, the increase in <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha and monocyte chemoattractant protein-1 in the ischemic brain was less in Agtr2 (+)-MSC-treated mice in the ipsilateral site, but was similar in the contralateral hemisphere </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha level was increased in both the contralateral hemisphere and ipsilateral hemisphere of Agtr2 (-)-MSC-treated mice </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, monocyte chemoattractant protein-1 levels tended to increase Agtr2 (-)-MSC-treated mice without a significant difference </plain></SENT>
<SENT sid="11" pm="."><plain>Treatment of MSC with an AT(1) receptor blocker, <z:chebi fb="0" ids="9927">valsartan</z:chebi>, significantly improved survival rates in Agtr2 (-)-MSC-injected mice </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: These results suggest that AT(2) receptor signaling in MSC attenuated brain damage and neurological deficit (deleted) </plain></SENT>
</text></document>